The Journal of Urology
Volume 172, Issue 3 , Pages 920-922 , September 2004

ANDROGEN REPLACEMENT AFTER CURATIVE RADICAL PROSTATECTOMY FOR PROSTATE CANCER IN HYPOGONADAL MEN

REFERENCES 

  1. Han M , Partin AW , Zahurak M , Piantadosi S , Epstein JI , Walsh PC . Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer . J Urol . 2003;169:517
  2. Arver S , Dobs AS , Meikle AW , Caramelli KE , Rajaram L , Sanders SW , et al.   Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men . Clin Endocrinol . 1997;47:727
  3. Cunningham GR , Hirshkowitz M , Korenman SG , Karacan I . Testosterone replacement therapy and sleep-related erections in hypogonadal men . J Clin Endocrinol Metab . 1990;70:792
  4. Hajjar RR , Kaiser FE , Morley JE . Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis . J Clin Endocrinol Metab . 1997;82:3793
  5. Davidson JM , Camargo CA , Smith ER . Effects of androgen on sexual behavior in hypogonadal men . J Clin Endocrinol Metab . 1979;48:955
  6. World Health Organization: 3rd International Consensus Consultation on Prostate Cancer, Paris, France, 2002
  7. Fowler JE , Whitmore WF . Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer . Cancer . 1982;49:1373
  8. Stanford JL , Stephenson RA , Coyle LM , Carol Kosary MA , Cerhan J , Correa R , et al.   Prostate Cancer Trends 1973–1995, SEER Program . Bethesda: National Institutes of Health, National Cancer Institute; 1999;
  9. Eaton NE , Reeves GK , Appleby PN , Key TJ . Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies . Br J Cancer . 1999;80:930
  10. Slater S , Oliver RT . Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy . Drugs Aging . 2000;17:431
  11. Gerstenbluth RE , Maniam PN , Corty EW , Seftel AD . Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement . J Androl . 2002;23:922
  12. Ludwig G . PADAM from the urologic viewpoint . Urologe A . 2000;39:407
  13. Morales A . Androgen replacement therapy and prostate safety . Eur Urol . 2002;41:113
  14. Wang C , Swedloff RS , Iranmanesh A , Dobs A , Snyder PJ , Cunningham G , et al.   Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group . J Clin Endocrinol Metab . 2000;85:2839
  15. Jackson JA , Waxman J , Spiekerman AM . Prostatic complications of testosterone replacement therapy . Arch Intern Med . 1989;149:2365
  16. Loughlin KR , Richie JP . Prostate cancer after exogenous testosterone treatment for impotence . J Urol . 1997;157:1845
  17. Curran MJ , Bihrle W . Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate . Urology . 1999;53:423

 Accepted for publication March 12, 2004.Supported by an unrestricted grant from Solvay Pharmaceuticals, Inc., Marietta, Georgia.

PII: S0022-5347(05)61522-4

doi: 10.1097/01.ju.0000136269.10161.32

The Journal of Urology
Volume 172, Issue 3 , Pages 920-922 , September 2004

Article Tools